Print
14 March 2017
GMP News
According to the analytical department of FBI SID&GP, by the end of 2016, 527 manufacturing licenses were effective in the Russian Federation, which corresponds to 566 production sites in 71 regions. At the same time, 378 sites (69%) have a license for manufacturing and packaging of finished dosage forms and substances, while 185 sites (31%) produce only alcohol-containing solutions, medical gases, etc. Moreover, due to various reasons, 42 sites were not engaged in pharmaceuticals manufacturing in 2016.
According to preliminary data of Rosstat, the overall growth of pharmaceutical industry in 2016 was 20%. This high production growth rate is confirmed by the data of independent analytical companies on the last year’s sales of medicinal products in the Russian pharmaceutical market.
For example, in 2016, the share of Russian manufacturers in the total market volume was 29% in monetary terms (or 284 billion rubles in wholesale prices) and 61% in physical terms (3.24 billion packages). Thus, it is possible to ascertain the growth of this indicator in monetary terms without significant changes in physical terms comparing to previous year (27% and 61%, respectively).
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.